Use of antidepressants in late-life depression

Drugs and Aging

Volumn 25, Issue 10, 2008, Pages 841-853

  Rajji, Tarek K ^a,b   Mulsant, Benoit H ^a,b,c   Lotrich, Francis E ^c   Lokker, Cynthia ^d   Reynolds III, Charles F ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d MCMASTER UNIVERSITY   (Canada)

Author keywords

Antidepressants, therapeutic use; Depression, treatment; Elderly

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; FLUOXETINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PLACEBO; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

AGING; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DISEASE COURSE; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; ELDERLY CARE; FOLLOW UP; HUMAN; LATE LIFE DEPRESSION; LIFE CYCLE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOTHERAPY; QUALITY OF LIFE; RELAPSE; REMISSION; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AGE FACTORS; AGED; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; HUMANS; MIDDLE AGED; MODELS, THEORETICAL; TREATMENT OUTCOME;

EID: 52449096919     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200825100-00003     Document Type: Review

References (154)

1. NIH consensus conference. Diagnosis and treatment of depression in late life. JAMA 1992; 268 (8): 1018-24
2. Lebowitz BD, Pearson JL, Schneider LS, et al. Diagnosis and treatment of depression in late life: consensus statement update. JAMA 1997; 278 (14): 1186-90
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed, text revision. Washington, DC: American Psychiatric Association, 2000
4. Mulsant BH, Ganguli M. Epidemiology and diagnosis of depression in late life. J Clin Psychiatry 1999; 60: 9-15
5. Steffens DC, Skoog I, Norton MC, et al. Prevalence of depression and its treatment in an elderly population: the Cache County Study. Arch Gen Psychiatry 2000; 57 (6): 601-7
6. Palsson SP, Ostling S, Skoog I. The incidence of first-onset depression in a population followed from the age of 70 to 85. Psychol Med 2001; 31 (7): 1159-68
7. Palsson S, Skoog I. The epidemiology of affective disorders in the elderly: a review. Int Clin Psychopharmacol 1997; 12: S3-13
8. Johnson J, Weissman MM, Klerman GL. Service utilization and social morbidity associated with depressive symptoms in the community. JAMA 1992; 267 (11): 1478-83
9. Blazer DG. Depression in late life: review and commentary. J Gerontol A Biol Sci Med Sci 2003; 58 (3): 249-65
10. Blazer D, Swartz M, Woodbury M, et al. Depressive symptoms and depressive diagnoses in a community population: use of a new procedure for analysis of psychiatric classification. Arch Gen Psychiatry 1988; 45 (12): 1078-84
11. Beekman ATF, Copeland JRM, Prince MJ. Review of community prevalence of depression in later life. Br J Psychiatry 1999; 174: 307-11
12. Barrett JE, Barrett JA, Oxman TE, et al. The prevalence of psychiatric disorders in a primary care practice. Arch Gen Psychiatry 1988; 45 (12): 1100-6
13. Murphy E. The prognosis of depression in old age. Br J Psychiatry 1983; 142: 111-9
14. Post F, Benson DF, Blumer D. Psychiatric aspects of neurologic disease. New York: Grune & Stratton Inc, 1998
15. Cole MG, Bellavance F, Mansour A. Prognosis of depression in elderly community and primary care populations: a systematic review and meta-analysis. Am J Psychiatry 1999; 156 (8): 1182-9
16. Forsell Y, Jorm AF, Winblad B. The outcome of depression and dysthymia in a very elderly population: results from a three-year follow-up study. Aging Ment Health 1998; 2 (2): 100-4
17. Sharma VK, Copeland JRM, Dewey ME, et al. Outcome of the depressed elderly living in the community in Liverpool: a 5-year follow-up. Psychol Med 1998; 28 (6): 1329-37
18. Stoudemire A, Hill CD, Marquardt M, et al. Recovery and relapse in geriatric depression after treatment with antidepressants and ECT in a medical-psychiatric population. Gen Hosp Psychiatry 1998; 20 (3): 170-4
19. Iber FL, Murphy PA, Connor ES. Age-related changes in the gastrointestinal system: effects on drug-therapy. Drugs Aging 1994; 5 (1): 34-48
20. Guelfi JD, Strub N, Loft H. Efficacy of intravenous citalopram compared with oral citalopram for severe depression: safety and efficacy data from a double-blind, double-dummy trial. J Affect Disord 2000; 58 (3): 201-9
21. Fryer J. Studies of body composition in men aged 60 and over. In: Shock N, editor. Biological aspects of aging. New York: Columbia University Press, 1962: 59-78
22. Lotrich FE, Pollock BG. Aging and clinical pharmacology: implications for antidepressants. J Clin Pharmacol 2005; 45 (10): 1106-22
23. Tsujimoto G, Hashimoto KHBB. Pharmacokinetic and pharmacodynamic principles of drug therapy in old age: part 2. Int J Clin Pharmacol Ther Toxicol 1989; 27: 102-16
24. Tune LE, Bylsma FW. Benzodiazepine-induced and anticholinergic-induced delirium in the elderly. Int Psychogeriatr 1991; 3: 397-408
25. Mets TF. Drug-induced orthostatic hypotension in older patients. Drugs Aging 1995; 6 (3): 219-28
26. Roose SP, Schatzberg AF. The efficacy of antidepressants in the treatment of late-life depression. J Clin Psychopharmacol 2005; 25 (4 Suppl. 1): S1-7
27. Mottram P, Wilson K, Strobl J. Antidepressants for depressed elderly. Cochrane Database Syst Rev 2006; (1): CD003491
28. Pinquart M, Duberstein PR, Lyness JM. Treatments for later-life depressive conditions: a meta-analytic comparison of pharmacotherapy and psychotherapy. Am J Psychiatry 2006; 163 (9): 1493-501
29. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991; 48 (9): 851-5
30. Rush AJ, Kraemer HC, Sackeim HA, et al. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 2006; 31 (9): 1841-53
31. Kupfer DJ. Long-term treatment of depression. J Clin Psychiatry 1991; 52 (5 Suppl.): 28-34
32. Riso LP, Thase ME, Howland RH, et al. A prospective test of criteria for response, remission, relapse, recovery, and recurrence in depressed patients treated with cognitive behavior therapy. J Affect Disord 1997; 43 (2): 131-42
33. Kayhan G, Nicolson R, MacDonald C, et al. Defining guilt in depression: a comparison of subjects with major depression, chronic medical illness and healthy controls. J Affect Disord 2002; 68 (2-3): 307-15
34. Zimmerman M, Chelminski I, Posternak M. A review of studies of the Hamilton depression rating scale in healthy controls: implications for the definition of remission in treatment studies of depression. J Nerv Ment Dis 2004; 192 (9): 595-601
35. Carmody TJ, Rush AJ, Bernstein I, et al. The Montgomery Asberg and the Hamilton ratings of depression: a comparison of measures. Eur Neuropsychopharmacol 2006; 16 (8): 601-11
36. Zimmerman M, Posternak MA, Chelminski I. Defining remission on the Montgomery-Asberg Depression Rating Scale. J Clin Psychiatry 2004; 65 (2): 163-8
37. Zimmerman M, Posternak MA, Chelminski W. Implications of using different cut-offs on symptom severity scales to define remission from depression. Int Clin Psychopharmacol 2004; 19 (4): 215-20
38. Rush AJ, Gullion CM, Basco MR, et al. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med 1996; 26 (3): 477-86
39. Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 2003; 54 (5): 573-83
40. Prien RF, Kupfer DJ. Continuation drug therapy for major depressive episodes: how long should it be maintained. Am J Psychiatry 1986; 143 (1): 18-23
41. Mulsant BH, Houck PR, Gildengers AG, et al. What is the optimal duration of a short-term antidepressant trial when treating geriatric depression? J Clin Psychopharmacol 2006; 26 (2): 113-20
42. Mulsant BH, Pollock BG, Nebes R, et al. A twelve-week, double-blind, randomized comparison of nortriptyline and paroxetine in older depressed inpatients and outpatients. Am J Geriatr Psychiatry 2001; 9 (4): 406-14
43. Brown MN, Lapane KL, Luisi AF. The management of depression in older nursing home residents. J Am Geriatr Soc 2002; 50 (1): 69-76
44. Wilson K, Mottram P. A comparison of side effects of selective serotonin reuptake inhibitors and tricyclic antidepressants in older depressed patients: a meta-analysis. Int J Geriatr Psychiatry 2004; 19 (8): 754-62
45. Flint AJ, Silveira J. Antidepressant use among elderly patients. Am J Psychiatry 2001; 158 (2): 328-a
46. Kane JM, Cole K, Sarantakos S, et al. Safety and efficacy of bupropion in elderly patients: preliminary observations. J Clin Psychiatry 1983; 44 (5 Pt 2): 134-6
47. Evans M, Hammond M, Wilson K, et al. Treatment of depression in the elderly: effect of physical illness on response. Int J Geriatr Psychiatry 1997; 12 (12): 1189-94
48. Wakelin JS. Fluvoxamine in the treatment of the older depressed patient; double-blind, placebo-controlled data. Int Clin Psychopharmacol 1986; 1 (3): 221-30
49. Rapaport MH, Schneider LS, Dunner DL, et al. Efficacy of controlled-release paroxetine in the treatment of late-life depression. J Clin Psychiatry 2003; 64 (9): 1065-74
50. Nair NPV, Amin M, Holm P, et al. Moclobemide and nortriptyline in elderly depressed patients: a randomized, multicentre trial against placebo. J Affect Disord 1995; 33 (1): 1-9
51. Georgotas A, McCue RE, Friedman E, et al. Response of depressive symptoms to nortriptyline, phenelzine and placebo. Br J Psychiatry 1987; 151: 102-6
52. Branconnier RJ, Cole JO, Ghazvinian S, et al. Clinical pharmacology of bupropion and imipramine in elderly depressives. J Clin Psychiatry 1983; 44 (5 Pt 2): 130-3
53. Cohn JB, Varga L, Lyford A. A two-center double-blind study of nomifensine, imipramine, and placebo in depressed geriatric outpatients. J Clin Psychiatry 1984; 45: 68-72
54. Nyth AL, Gottfries CG, Lyby K, et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 1992; 86 (2): 138-45
55. Schweizer E, Rickels K, Hassman H, et al. Buspirone and imipramine for the treatment of major depression in the elderly. J Clin Psychiatry 1998; 59 (4): 175-83
56. Halikas JA. Org-3770 (mirtazapine) versus trazodone: a placebo-controlled trial in depressed elderly patients. Hum Psychopharmacol Clin Exp 1995; 10: S125-33
57. Merideth CH, Feighner JP, Hendrickson G. A double-blind comparative evaluation of the efficacy and safety of nomifensine, imipramine, and placebo in depressed geriatric outpatients. J Clin Psychiatry 1984; 45 (4): 73-7
58. Gerner R, Estabrook W, Steuer J, et al. Treatment of geriatric depression with trazodone, imipramine, and placebo: a double-blind study. J Clin Psychiatry 1980; 41 (6): 216-20
59. Georgotas A, McCue RE, Hapworth W, et al. Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly. Biol Psychiatry 1986; 21 (12): 1155-66
60. Entsuah AR, Huang H, Thase ME. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo. J Clin Psychiatry 2001; 62 (11): 869-77
61. Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007; 164 (6): 900-9
62. Nelson JC, Wohlreich MM, Mallinckrodt CH, et al. Duloxetine for the treatment of major depressive disorder in older patients. Am J Geriatr Psychiatry 2005; 13 (3): 227-35
63. Tollefson GD, Bosomworth JC, Heiligenstein JH, et al. A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression: the Fluoxetine Collaborative Study Group. Int Psychogeriatr 1995; 7 (1): 89-104
64. Petracca GM, Chemerinski E, Starkstein SE. A double-blind, placebo-controlled study of fluoxetine in depressed patients with Alzheimer's disease. Int Psychogeriatr 2001; 13 (2): 233-40
65. Roose SP, Sackeim HA, Krishnan KR, et al. Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. Am J Psychiatry 2004; 161 (11): 2050-9
66. Schatzberg A, Roose S. A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression. Am J Geriatr Psychiatry 2006; 14 (4): 361-70
67. Kasper S, de Swart H, Andersen HF. Escitalopram in the treatment of depressed elderly patients. Am J Geriatr Psychiatry 2005; 13 (10): 884-91
68. Cohn CK, Shrivastava R, Mendels J, et al. Double-blind, multicenter comparison of sertraline and amitriptyline in elderly depressed patients. J Clin Psychiatry 1990; 51 Suppl. B: 28-33
69. Dunner DL, Cohn JB, Walshe T, et al. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. J Clin Psychiatry 1992; 53: 57-60
70. Feighner JP, Cohn JB. Double-blind comparative trials of fluoxetine and doxepin in geriatric patients with major depressive disorder. J Clin Psych 1985; 46 (3 Pt 2): 20-5
71. Hutchinson DR, Tong S, Moon CA, et al. Paroxetine in the treatment of elderly depressed patients in general practice: a double-blind comparison with amitriptyline. Int Clin Psychopharmacol 1992; 6 Suppl. 4: 43-51
72. Guillibert E, Pelicier Y, Archambault JC, et al. A double-blind, multicentre study of paroxetine versus clomipramine in depressed elderly patients. Acta Psychiatr Scand Suppl 1989; 350: 132-4
73. Altamura AC, De Novellis F, Guercetti G, et al. Fluoxetine compared with amitriptyline in elderly depression: a controlled clinical trial. Int J Clin Pharmacol Res 1989; 9 (6): 391-6
74. Kyle CJ, Petersen HE, Overø KF. Comparison of the tolerability and efficacy of citalopram and amitriptyline in elderly depressed patients treated in general practice. Depress Anxiety 1998; 8 (4): 147-53
75. Bondareff W, Alpert M, Friedhoff AJ, et al. Comparison of sertraline and nortriptyline in the treatment of major depressive disorder in late life. Am J Psychiatry 2000; 157 (5): 729-36
76. Pelicier Y, Schaeffer P. A multi-center, blind study to compare the efficacy and tolerability of paroxetine and clomipramine in elderly patients with reactive depression. Encephale 1993; 19: 257-61
77. Geretsegger C, Fartacek R, Stuppaeck C, et al. Multicenter double blind study of paroxetine and amitriptyline in elderly depressed inpatients. Psychopharmacology 1995; 119 (3): 277-81
78. Nelson JC, Kennedy JS, Pollock BG, et al. Treatment of major depression with nortriptyline and paroxetine in patients with ischemic heart disease. Am J Pyschiatry 1999; 156 (7): 1024-8
79. Taragano FE, Lyketsos CG, Mangone CA, et al. A double-blind, randomized, fixed-dose trial of fluoxetine vs. amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics 1997; 38 (3): 246-52
80. Wehmeier PM, Kluge M, Maras A, et al. Fluoxetine versus trimipramine in the treatment of depression in geriatric patients. Pharmacopsychiatry 2005; 38 (1): 13-6
81. Phanjoo A. The elderly depressed and treatment with fluvoxamine. Int Clin Psychopharmacol 1991; 6: 33-9
82. Rahman MK, Akhtar MJ, Savla NC, et al. A double-blind, randomized comparison of fluvoxamine with dothiepin in the treatment of depression in elderly patients. Br J Clin Pract 1991; 45 (4): 255-8
83. Katona CLE, Hunter BN, Bray J. A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry 1998; 13 (2): 100-8
84. Dunbar GC. Paroxetine in the elderly: a comparative meta-analysis against standard antidepressant pharmacotherapy. Pharmacology 1995; 51 (3): 137-44
85. Mulsant BH, Pollock BG, Nebes RD, et al. A double-blind randomized comparison of nortriptyline and paroxetine in the treatment of late-life depression: 6-week outcome. J Clin Psychiatry 1999; 60: 16-20
86. Forlenza OV, Almeida OP, Stoppe A, et al. Antidepressant efficacy and safety of low-dose sertraline and standard-dose imipramine for the treatment of depression in older adults: results from a double-blind, randomized, controlled clinical trial. Int Psychogeriatr 2001; 13 (1): 75-84
87. Trick L, Stanley N, Rigney U, et al. A double-blind, randomnized, 26-week study comparing the cognitive and psychomotor effects and efficacy of 75mg (37.5mg b.i.d.) venlafaxine and 75mg (25mg mane mg, 50 nocte) dothiepin in elderly patients with moderate major depression being treated in general practice. J Psychopharmacol 2004; 18 (2): 205-14
88. Katona C, Bercoff E, Chiu E, et al. Reboxetine versus imiprameine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial. J Affect Disord 1999; 55 (2-3): 203-13
89. Hoyberg OJ, Maragakis B, Mullin J, et al. A double-blind multicentre comparison of mirtazapine and amitriptyline in elderly depressed patients. Acta Psychiatr Scand 1996; 93 (3): 184-90
90. Gasto C, Navarro V, Marcos T, et al. Single-blind comparison of venlafaxine and nortriptyline in elderly major depression. J Clin Psychopharmacol 2003; 23 (1): 21-6
91. Mahapatra SN, Hackett D. A randomised, double-blind, parallel-group comparison of venlafaxine and dothiepin in geriatric patients with major depression. Int J Clin Pract 1997; 51 (4): 209-13
92. Smeraldi E, Rizzo F, Crespi G. Double-blind, randomized study of venlafaxine, clomipramine and trazodone in geriatric patients with major depression. Prim Care Psychiatry 1998; 4: 189-95
93. Schone W, Ludwig M. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression. J Clin Psychopharmacol 1993; 13 (6): S34-9
94. Newhouse PA, Krishnan KR, Doraiswamy PM, et al. A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients. J Clin Psychiatry 2000; 61 (8): 559-68
95. Trappler B, Cohen CI. Use of SSRIs in "very old" depressed nursing home residents. Am J Geriatr Psychiatry 1998; 6 (1): 83-9
96. Rossini D, Serretti A, Franchini L, et al. Sertraline versus fluvoxamine in the treatment of elderly patients with major depression: a double-blind, randomized trial. J Clin Psychopharmacol 2005; 25 (5): 471-5
97. Weihs KL, Settle EC, Batey SR, et al. Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry 2000; 61 (3): 196-202
98. Doraiswamy PM, Khan ZM, Donahue RMJ, et al. Quality of life in geriatric depression: a comparison of remitters, partial responders, and nonresponders. Am J Geriatr Psychiatry 2001; 9 (4): 423-8
99. Rampello L, Chiechio S, Nicoletti G, et al. Prediction of the response to citalopram and reboxetine in post-stroke depressed patients. Psychopharmacology 2004; 173 (1-2): 73-8
100. Schatzberg AF, Cantillon M. Antidepressant early response and remission of venlafaxine and fluoxetine in geriatric outpatients. Eur Neuropsychopharmacol 2000; 10 Suppl. 3: 225-6
101. Allard P, Gram L, Timdahl K, et al. Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram. Int J Geriatr Psychiatry 2004; 19 (12): 1123-30
102. Hwang JP, Yang CH, Tsai SJ. Comparison study of venlafaxine and paroxetine for the treatment of depression in elderly Chinese inpatients. Int J Geriatr Psychiatry 2004; 19 (2): 189-90
103. Navarro V, Gasto C, Torres X, et al. Citalopram versus nortriptyline in late-life depression: a 12-week randomized single-blind study. Acta Psychiatr Scand 2001; 103 (6): 435-40
104. Oslin DW, Streim JE, Katz IR, et al. Heuristic comparison of sertraline with nortriptyline for the treatment of depression in frail elderly patients. Am J Geriatr Psychiatry 2000; 8 (2): 141-9
105. Finkel SI, Richter EM, Clary CM. Comparative efficacy and safety of sertraline versus nortriptyline in major depression in patients 70 and older. Int Psychogeriatr 1999; 11 (1): 85-99
106. Dalery J, Aubin V. Comparative study of paroxetine and mianserine in depression of the elderly: efficacy, tolerance, serotonine dependence. Encephale-Revue de Psychiatrie Clinique Biologique et Therapeutique 2001; 27 (1): 71-81
107. Roose SP, Glassman AH, Attia E, et al. Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 1994; 151 (12): 1735-9
108. Schatzberg AF, Kremer C, Rodrigues HE, et al. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry 2002; 10 (5): 541-50
109. Katz IR, Simpson GM, Curlik SM, et al. Pharmacologic treatment of major depression for elderly patients in residential care settings. J Clin Psychiatry 1990; 51 Suppl.: 41-7
110. Osli DW, Ten Have TR, Streim JE, et al. Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. J Clin Psychiatry 2003; 64 (8): 875-82
111. Nelson JC, Hollander SB, Betzel J, et al. Mirtazapine orally disintegrating tablets in depressed nursing home residents 85 years of age and older. Int J Geriatr Psychiatry 2006; 21 (9): 898-901
112. Reynolds III CF, Miller MD, Pasternak RE, et al. Treatment of bereavement-related major depressive episodes in later life: a controlled study of acute and continuation treatment with nortriptyline and interpersonal psychotherapy. Am J Psychiatry 1999; 156 (2): 202-8
113. Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995; 25 (6): 1171-80
114. Lyketsos CG, DelCampo L, Steinberg M, et al. Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS. Arch Gen Psychiatry 2003; 60 (7): 737-46
115. Reynolds III CF, Frank E, Kupfer DJ, et al. Treatment outcome in recurrent major depression: a post-hoc comparison of elderly ("young old") and midlife patients. Am J Psychiatry 1996; 153 (10): 1288-92
116. Schneider LS, Nelson JC, Clary CM, et al. An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. Am J Psychiatry 2003; 160 (7): 1277-85
117. Reynolds CF, Frank E, Perel JM, et al. Combined pharmacotherapy and psychotherapy in the acute and continuation treatment of elderly patients with recurrent major depression: a preliminary report. Am J Psychiatry 1992; 149 (12): 1687-92
118. Malt UF, Robak OH, Madsbu HP, et al. The Norwegian naturalistic treatment study of depression in general practice (NORDEP)-I: randomized double blind study. BMJ 1999; 318 (7192): 1180-4
119. Rapp SR, Parisi SA, Wallace CE. Comorbid psychiatric disorders in elderly medical patients: a 1-year prospective study. J Am Geriatr Soc 1991; 39 (2): 124-31
120. Miller MD, Frank E, Reynolds CF. The art of clinical management in pharmacologic trials with depressed elderly patients: lessons from the Pittsburgh Study of Maintenance Therapies in Late-Life Depression. Am J Geriatr Psychiatry 1999; 7 (3): 228-34
121. Barrett JE, Williams JW, Oxman TE, et al. Effectiveness of paroxetine and problem solving treatment for PC patients with minor depression or dysthymia. Int J Psychiatry Med 1999; 29 (4): 359-60
122. Williams Jr JW, Barrett J, Oxman T, et al. Treatment of dysthymia and minor depression in primary care: a randomized controlled trial in older adults. JAMA 2000; 284 (12): 1519-26
123. Parnetti L, Sommacal S, Labate AMM, et al. Multicenter controlled randomized double-blind placebo study of minaprine in elderly patients suffering from prolonged depressive reaction. Drug Invest 1993; 6 (4): 181-8
124. Devanand DP, Nobler MS, Cheng J, et al. Randomized, double-blind, placebo-controlled trial of fluoxetine treatment for elderly patients with dysthymic disorder. Am J Geriatr Psychiatry 2005; 13 (1): 59-68
125. Burrows AB, Salzman C, Satlin A, et al. A randomized, placebo-controlled trial of paroxetine in nursing home residents with non-major depression. Depress Anxiety 2002; 15 (3): 102-10
126. Devanand DP, Juszczak N, Nobler MS, et al. Open treatment trial of venlafaxine for elderly patients with dysthymic disorder. J Geriatr Psychiatry Neurol 2004; 17 (4): 219-24
127. Lyness JM, Heo M, Datto CJ, et al. Outcomes of minor and subsyndromal depression among elderly patients in primary care settings. Ann Intern Med 2006; 144 (7): 496-504
128. Jacoby R, Lunn AD, Ardern M, et al. How long should the elderly take antidepressants: a double-controlled study of continuation prophylaxis therapy with dothiepin. Br J Psychiatry 1993; 162: 175-82
129. Georgotas A, McCue RE, Cooper TB, et al. How effective and safe is continuation therapy in elderly depressed patients? Factors affecting relapse rate. Arch Gen Psychiatry 1988; 45 (10): 929-32
130. Hinrichsen GA. Recovery and relapse from major depressive disorder in the elderly. Am J Psychiatry 1992; 149 (11): 1575-9
131. Flint AJ, Rifat SL. The effect of treatment on the two-year course of late-life depression. Br J Psychiatry 1997; 170: 268-72
132. Flint AJ, Rifat SL. Maintenance treatment for recurrent depression in late life: a four-year outcome study. Am J Geriatr Psychiatry 2000; 8 (2): 112-6
133. Flint AJ, Rifat SL. Recurrence of first-episode geriatric depression after discontinuation of maintenance antidepressants. Am J Psychiatry 1999; 156 (6): 943-5
134. Georgotas A, McCue RE, Cooper TB. A placebo-controlled comparison of nortriptyline and phenelzine in maintenance therapy of elderly depressed patients. Arch Gen Psychiatry 1989; 46 (9): 783-6
135. Gorwood P, Weiller E, Lemming O, et al. Escitalopram prevents relapse in older patients with major depressive disorder. Am J Geriatr Psychiatry 2007; 15 (7): 581-93
136. Klysner R, Bent-Hansen J, Hansen HL, et al. Efficacy of citalopram in the prevention of recurrent depression in elderly patients: placebo-controlled study of maintenance therapy. Br J Psychiatry 2002; 181: 29-35
137. Reynolds III CF, Dew MA, Pollock BG, et al. Maintenance treatment of major depression in old age. N Engl J Med 2006; 354 (11): 1130-8
138. Reynolds III CF, Frank E, Perel JM, et al. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. JAMA 1999; 281 (1): 39-45
139. Reynolds III CF, Perel JM, Frank E, et al. Three-year outcomes of maintenance nortriptyline treatment in late-life depression: a study of two fixed plasma levels. Am J Psychiatry 1999; 156 (8): 1177-81
140. Wilson KCM, Mottram PG, Ashworth L, et al. Older community residents with depression: long-term treatment with sertraline: randomised, double-blind, placebo-controlled study. Br J Psychiatry 2003; 182 (6): 492-7
141. Gallo JJ, Bogner HR, Morales KH, et al. The effect of a primary care practice-based depression intervention on mortality in older adults: a randomized trial. Ann Intern Med 2007; 146 (10): 689-98
142. Bogner HR, Morales KH, Post EP, et al. Diabetes, depression, and death: a randomized controlled trial of a depression treatment program for older adults based in primary care (PROSPECT). Diabetes Care 2007; 30 (12): 3005-10
143. Alexopoulos GS, Katz IR, Reynolds III CF, et al. Pharmacotherapy of depression in older patients: a summary of the expert consensus guidelines. J Psychiatr Pract 2001; 7 (6): 361-76
144. Mulsant BH, Alexopoulos GS, Reynolds CF, et al. Pharmacological treatment of depression in older primary care patients: the PROSPECT algorithm. Int J Geriatr Psychiatry 2001; 16 (6): 585-92
145. Whyte EM, Basinski J, Farhi P, et al. Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors. J Clin Psychiatry 2004; 65 (12): 1634-41
146. Dew MA, Whyte EM, Lenze EJ, et al. Recovery from major depression in older adults receiving augmentation of antidepressant pharmacotherapy. Am J Psychiatry 2007; 164 (6): 892-9
147. Flint AJ, Rifat SL. The effect of sequential antidepressant treatment on geriatric depression. J Affect Disord 1996; 36 (3-4): 95-105
148. Sunderland T, Cohen RM, Molchan S, et al. High-dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatry 1994; 51 (8): 607-15
149. Kok RM, Vink D, Heeren TJ, et al. Lithium augmentation compared with phenelzine in treatment-resistant depression in the elderly: an open, randomized, controlled trial. J Clin Psychiatry 2007; 68 (8): 1177-85
150. Rutherford B, Sneed J, Miyazaki M, et al. An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression. Int J Geriatr Psychiatry 2007; 22 (10): 986-91
151. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163 (11): 1905-17
152. Johnson EM, Whyte E, Mulsant BH, et al. Cardiovascular changes associated with venlafaxine in the treatment of late-life depression. Am J Geriatr Psychiatry 2006; 14 (9): 796-802
153. Baldwin RC. Refractory depression in late life: a review of treatment options. Rev Clin Gerontol 1996; 6 (4): 343-8
154. Lavretsky H, Park S, Siddarth P, et al. Methylphenidate-enhanced antidepressant response to citalopram in the elderly: a double-blind, placebo-controlled pilot trial. Am J Geriatr Psychiatry 2006; 14 (2): 181-5